Tag: ACCESS 2
CX 2025: Sirolimus implant fails to meet fistula maturation endpoint in...
Results of the ACCESS 2 study, evaluating arteriovenous fistula (AVF) outcomes following use of the Sirogen (Vascular Therapies) sirolimus-eluting collagen implant, have shown that...
Vascular Therapies completes enrolment in the ACCESS 2 study
Vascular Therapies has today announced completion of enrolment in the ACCESS 2 trial, a Phase III prospective randomised, multicentre clinical study of Sirogen for the...
Sirogen™: A potential solution for improving arteriovenous fistula maturation
This advertorial is sponsored by Vascular Therapies
Arteriovenous fistula (AVF) maturation is a pivotal event in patients requiring haemodialysis. Maximising the number of fistulas that...
Vascular Therapies closes US$25 million in private financing to advance proprietary...
Vascular Therapies today announced the closing of US$25 million in private financing. The financing in question comprised of both existing and new investors, including...